GSEP
RLMD icon

Golden State Equity Partners’s Relmada Therapeutics RLMD Stock Holding History

Golden State Equity Partners’s Portfolio RLMD Stock Details RLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-200
Closed -$648 – 770
2024
Q3 		$648 Buy
+200
New +$648 ﹤0.01% 776
2022
Q1 		$334K Buy
12,375
+50
+0.4% +$1.03K 0.17% 142
2021
Q4 		$278K Buy
+12,325
New +$274K 0.14% 136

Other funds holding RLMD

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Golden State Equity Partners's RLMD Position: Q4 2024 in Review

Golden State Equity Partners sold out of Relmada Therapeutics (RLMD) in Q4 2024, closing a stake of 200 shares — an estimated $648 sold.

Golden State Equity Partners first reported a position in RLMD in Q4 2021 and held it in 3 quarters. The position peaked at $334K in Q1 2022. 48 funds tracked by Wall St. Rank hold RLMD as of Q4 2024.

  • Golden State Equity Partners reported no remaining Relmada Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Golden State Equity Partners sold 200 Relmada Therapeutics shares in Q4 2024, an estimated $648.
  • Golden State Equity Partners first reported a position in Relmada Therapeutics in Q4 2021 and held it in 3 quarters.
  • Golden State Equity Partners's Relmada Therapeutics position peaked at $334K in Q1 2022.
  • 48 funds tracked by Wall St. Rank held Relmada Therapeutics as of Q4 2024.

Based on Golden State Equity Partners's 13F filing for Q4 2024, filed 24 Jan 2025.